← Leaderboards
Frank W. Marcoux
Leukogene Therapeutics, Inc.
$2,447,659
Attributed
$2,447,659
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2013–19$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,447,659 · 3
By mechanism
R42$2,000,000 · 1
R41$447,659 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeExpectationPharmaceutical ChemistryProteasome InhibitorPositioning AttributePlasma CellsMouse ModelNormal CellPharmaceutical PreparationsPropertyToxic EffectIn VivoBaseLeadDesignMolecularDrug TargetingMultiple MyelomaCellsMalignant NeoplasmsIn VitroClinical TrialsInhibitor/AntagonistMetabolic
Grant awards (4)
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma$1,015,871
R42 · FY2019 · CA · contact PI
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma$984,129
R42 · FY2018 · CA · contact PI
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma$222,958
R41 · FY2016 · CA · contact PI
Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma$224,701
R41 · FY2013 · CA · contact PI